A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.

The present invention discloses a compound heparin anticoagulant coating liquid, a microsphere for coating and its preparation methods and applications. In the present invention, the combination of curcumin and heparin can enhance the anticoagulation functions of heparin coating, and further enhance the stability using the properties of PLA-PEG-PLA drug-loaded sustained-release microspheres, achieving the functions of anti-tissue proliferation and anti-inflammatory reactions that cannot be achieved by coatings alone such as heparin or protein, which is very important for implanted devices such as artificial blood vessels, vascular stents and vascular patches to reduce thrombosis in the human body, lower postoperative complications and improve product lifespan.

Disclosed is a high anticoagulation ECMO and extracorporeal circulation consumable, which include the following preparation methods: S1, aminating the surface of ECMO blood circulation device and extracorporeal circulation consumables; S2, activating heparin groups; S3, heparinizing the ECMO blood circulation device and extracorporeal circulation consumables; S4, modification of enhancer. The application can produce a novel high anticoagulation extracorporeal circulation tube with low price and high biocompatibility, which expands the application in clinic.

Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.

The present invention relates to novel compositions and methods for reducing or eliminating the thrombogenicity of a graft by modifying the graft with a cell-derived extracellular matrix lacking thrombospondin-2 (TSP2-null ECM) to render it non-thrombogenic when transplanted to a subject in need thereof. The invention also provides a method for improving the biocompatibility of a medical device or an implant by modifying the medical device or implant with a cell-derived TSP2-null ECM, whereby the medical device or implant is rendered non-thrombogenic and pro-migratory.

The invention discloses a recombinant complement factor H (CFH)-immunoglobulin (Ig) fusion protein CFH-Ig with complement regulating activity, more specifically, complement regulating activity in the alternative complement pathway, and at the same time with the effect of targeting to tissues or cells where there is overactivation of complement. The invention further relates to a method for preparation of the fusion protein. The invention also relates to a pharmaceutical composition that contains the aforementioned fusion protein for treating autoimmune diseases or other diseases mediated by, or caused by disregulation or deficiency in the alternative complement pathway, as well as preventing or treating thrombosis caused by excessive complement activation in humans or other mammals.

Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.

An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.